Publications by authors named "Deepthi S Vagge"
Cold agglutinin disease (CAD) is a rare, autoimmune, classical complement pathway (CP)-mediated hemolytic anemia. Sutimlimab selectively inhibits C1s of the C1 complex, preventing CP activation while leaving the alternative and lectin pathways intact. In Part A (26 weeks) of the open-label, single-arm, Phase 3 CARDINAL study in patients with CAD and a recent history of transfusion, sutimlimab demonstrated rapid effects on hemolysis and anemia.
View Article and Find Full Text PDFArticle Synopsis
- * The study found that 73% of patients receiving sutimlimab met the primary effectiveness criteria, significantly improving hemoglobin levels and reducing symptoms compared to only 15% of those on placebo.
- * While sutimlimab showed promising results, some patients experienced more side effects, including headaches and hypertension, highlighting the need for careful monitoring in clinical use.